Skip to main content
OpenTrials

Clinical trial condition

Sexual Dysfunctions, Psychological

Explore clinical trials studying Sexual Dysfunctions, Psychological. Study availability and eligibility vary by location and protocol.

28 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Sexual Dysfunctions, Psychological trial results

Completed

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360529

Conditions
Mental Disorders, Sexual Dysfunctions, Psychological
Locations
  • 511.71.01034 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 511.71.01042 Boehringer Ingelheim Investigational Site South Birmingham, Alabama, United States
  • 511.71.01016 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • 511.71.01041 Boehringer Ingelheim Investigational Site La Mesa, California, United States
View all 54 locations
View Trial Details
Completed

6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

NCT00360243

Conditions
Mental Disorders, Sexual Dysfunctions, Psychological
Locations
  • 511.70.01068 Boehringer Ingelheim Investigational Site Huntsville, Alabama, United States
  • 511.70.01040 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 511.70.01041 Boehringer Ingelheim Investigational Site Tucson, Arizona, United States
  • 511.70.01003 Boehringer Ingelheim Investigational Site Jonesboro, Arkansas, United States
View all 81 locations
View Trial Details
Completed

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360555

Conditions
Mental Disorders, Sexual Dysfunctions, Psychological
Locations
  • 511.75.01015 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 511.75.01028 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 511.75.01051 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • 511.75.01063 Boehringer Ingelheim Investigational Site Little Rock, Arkansas, United States
View all 77 locations
View Trial Details
Completed

Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

NCT00601367

Conditions
Mental Disorders, Sexual Dysfunctions, Psychological
Locations
  • 511.118.43005 Boehringer Ingelheim Investigational Site Innsbruck, Austria
  • 511.118.43002 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 511.118.43004 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 511.118.43006 Boehringer Ingelheim Investigational Site Wörgl, Austria
View all 68 locations
View Trial Details
Completed

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00996372

Conditions
Mental Disorders, Sexual Dysfunctions, Psychological
Locations
  • 511.130.01074 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 511.130.01046 Boehringer Ingelheim Investigational Site Huntsville, Alabama, United States
  • 511.130.01042 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 511.130.01025 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
View all 75 locations
View Trial Details
Completed

Flibanserin Versus Placebo in Premenopausal Women With HSDD

NCT00491829

Conditions
Mental Disorders, Sexual Dysfunctions, Psychological
Locations
  • 511.77.43005 Boehringer Ingelheim Investigational Site Innsbruck, Austria
  • 511.77.43001 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 511.77.43002 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 511.77.43004 Boehringer Ingelheim Investigational Site Vienna, Austria
View all 86 locations
View Trial Details
Completed

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

NCT01188603

Conditions
Mental Disorders, Sexual Dysfunctions, Psychological
Locations
  • 511.146.01003 Boehringer Ingelheim Investigational Site Orlando, Florida, United States
  • 511.146.01005 Boehringer Ingelheim Investigational Site Wichita, Kansas, United States
  • 511.146.01001 Boehringer Ingelheim Investigational Site Kalamazoo, Michigan, United States
  • 511.146.01004 Boehringer Ingelheim Investigational Site Knoxville, Tennessee, United States
View Trial Details

Related conditions